CTLA4 and melanoma: According to the results, the transcriptome profiles of C3 and melanoma patients who responded to anti-CTLA4 immunotherapy were highly similar (P = 0.006, Bonferroni adjusted P = 0.072, FDR adjusted P = 0.072; Figure 4E).